STOK Stock Analysis
ST
Uncovered
Stoke Therapeutics Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.796
Dividend yield
—
Shares outstanding
44.148 B
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 117 full-time employees. The company went IPO on 2019-06-19. The firm is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. The Company’s STK-001, is for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. Its STK-002 is a proprietary antisense oligonucleotide (ASO) in preclinical development for the treatment of Autosomal Dominant Optic Atrophy (ADOA). STK-002 is designed to upregulate OPA1 protein expression by leveraging the non-mutant copy of the OPA1 gene to restore OPA1 protein expression with the aim to stop or slow vision loss in patients with ADOA. The firm develops the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health.